Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Sung-Hyun | - |
dc.contributor.author | Lim, Key-Hwan | - |
dc.contributor.author | Yang, Sumin | - |
dc.contributor.author | Joo, Jae-Yeol | - |
dc.date.accessioned | 2023-08-16T09:31:20Z | - |
dc.date.available | 2023-08-16T09:31:20Z | - |
dc.date.created | 2022-01-11 | - |
dc.date.issued | 2021-05 | - |
dc.identifier.issn | 1756-8722 | - |
dc.identifier.uri | http://scholarworks.bwise.kr/kbri/handle/2023.sw.kbri/330 | - |
dc.description.abstract | Brain tumors are associated with adverse outcomes despite improvements in radiation therapy, chemotherapy, and photodynamic therapy. However, treatment approaches are evolving, and new biological phenomena are being explored to identify the appropriate treatment of brain tumors. Long non-coding RNAs (lncRNAs), a type of non-coding RNA longer than 200 nucleotides, regulate gene expression at the transcriptional, post-transcriptional, and epigenetic levels and are involved in a variety of biological functions. Recent studies on lncRNAs have revealed their aberrant expression in various cancers, with distinct expression patterns associated with their instrumental roles in cancer. Abnormal expression of lncRNAs has also been identified in brain tumors. Here, we review the potential roles of lncRNAs and their biological functions in the context of brain tumors. We also summarize the current understanding of the molecular mechanisms and signaling pathways related to lncRNAs that may guide clinical trials for brain tumor therapy. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC | - |
dc.title | Long non-coding RNAs in brain tumors: roles and potential as therapeutic targets | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Sung-Hyun | - |
dc.contributor.affiliatedAuthor | Lim, Key-Hwan | - |
dc.contributor.affiliatedAuthor | Yang, Sumin | - |
dc.contributor.affiliatedAuthor | Joo, Jae-Yeol | - |
dc.identifier.doi | 10.1186/s13045-021-01088-0 | - |
dc.identifier.scopusid | 2-s2.0-85105714720 | - |
dc.identifier.wosid | 000656445600001 | - |
dc.identifier.bibliographicCitation | JOURNAL OF HEMATOLOGY & ONCOLOGY, v.14, no.1 | - |
dc.relation.isPartOf | JOURNAL OF HEMATOLOGY & ONCOLOGY | - |
dc.citation.title | JOURNAL OF HEMATOLOGY & ONCOLOGY | - |
dc.citation.volume | 14 | - |
dc.citation.number | 1 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | HUMAN GLIOMA-CELLS | - |
dc.subject.keywordPlus | MALIGNANT BIOLOGICAL BEHAVIORS | - |
dc.subject.keywordPlus | LNCRNA SBF2-AS1 PROMOTES | - |
dc.subject.keywordPlus | IMMUNE-RELATED LNCRNA | - |
dc.subject.keywordPlus | NF-KAPPA-B | - |
dc.subject.keywordPlus | EXTRACELLULAR VESICLES | - |
dc.subject.keywordPlus | POOR-PROGNOSIS | - |
dc.subject.keywordPlus | GLIOBLASTOMA CELL | - |
dc.subject.keywordPlus | ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | CANCER METASTASIS | - |
dc.subject.keywordAuthor | Brain disease | - |
dc.subject.keywordAuthor | Genomics | - |
dc.subject.keywordAuthor | Glioma | - |
dc.subject.keywordAuthor | LncRNA | - |
dc.subject.keywordAuthor | Neurodegenerative disease | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
61, Cheomdan-ro, Dong-gu, Daegu, Republic of Korea , 41062 053-980-8114
COPYRIGHT Korea Brain Research Institute. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.